Agilent Technologies Inc (NYSE:A) stock rose 3.39% (As on November 25, 11:36:34 AM UTC-4, Source: Google Finance) after the company beat fourth-quarter revenue estimates, helped by strong demand for medical tools and equipment used in lab research and diagnostic services. Medical equipment makers have seen renewed demand for contract research and diagnostics services, as pharmaceutical companies accelerate drug development in the U.S. amid President Donald Trump’s shifting trade policies. Non-GAAP net income was $452 million during the quarter, compared with $418 million during the year-ago quarter.
Moreover, the Agilent CrossLab Group reported fourth-quarter revenue of $755 million, up 7% YoY, while the Applied Markets Group saw revenue increase 4% to $351 million. The company’s performance was driven by its customer-focused approach and unified commercial organization, which McDonnell noted “continue to unlock operating efficiencies, fuel innovation, enhance commercial execution, and create long-term value.” The Life Sciences and Diagnostics Markets Group (LDG) reported fourth-quarter revenue of $755 million, an increase of 15% reported and 11% core year-over-year. LDG’s operating margin for the quarter was 22.7%. Momentum remained broad-based across the portfolio, supported by strong LC and LC/MS demand and share gains, CDMO upside, solid double-digit contributions in key regions and a replacement cycle that continues to accelerate. At the same time, the Ignite Operating System continues to improve the effectiveness and efficiency of the organization. Ignite helped deliver more than 200 basis points of sequential margin improvement compared with last quarter — while funding incremental performance-driven variable pay. The cross-functional task force rapidly developed a unified strategy and executed a suite of interconnected projects that greatly accelerated the tariff-mitigation efforts. As a result, the company is highly confident that the company will fully mitigate current tariffs in FY26
A in the fourth quarter of FY25 has reported the adjusted earnings per share of $1.59, beating the analysts’ estimates for the adjusted earnings per share of $1.58, according to analysts polled by FactSet. The company had reported the adjusted revenue growth of 9.4 percent to $1.86 billion in the fourth quarter of FY25, beating the analysts’ estimates for revenue of $1.83 billion.
Looking ahead, the company provided fiscal 2026 revenue guidance of $7.3 billion to $7.4 billion, representing growth of 5% to 7%, with adjusted EPS expected between $5.86 and $6.00. Analysts expect EPS of $6.02 on revenue of $7.29 billion. For the first quarter of fiscal 2026, Agilent expects revenue between $1.79 billion and $1.82 billion, with adjusted EPS of $1.35 to $1.38.